| Literature DB >> 29808581 |
Maria Angélica Martins Lourenço1, Mariana Gobbo Braz2, Aline Garcia Aun2, Bruna Letícia Buzati Pereira1, Amanda Menezes Figueiredo1, Renata Aparecida Cândido da Silva1, Elisa Moya Kazmarek1, Patrícia Helena Correa Alegre1, Tatiana Fernanda Bachiega1, Silmeia Garcia Zanati1, Paula Schmidt Azevedo1, Bertha Furlan Polegato1, Ana Angélica Henrique Fernandes3, Sergio Alberto Rupp de Paiva1, Leonardo Antonio Mamede Zornoff1, Marcos Ferreira Minicucci1.
Abstract
The objective of this study was to investigate the influence of Spondias mombin (SM) supplementation on the cardiac remodelling process induced by exposure to tobacco smoke (ETS) in rats. Male Wistar rats were divided into 4 groups: group C (control, n = 20) comprised animals not exposed to cigarette smoke and received standard chow; group ETS (n = 20) comprised animals exposed to cigarette smoke and received standard chow; group ETS100 (n = 20) received standard chow supplemented with 100 mg/kg body weight/d of SM; and group ETS250 (n = 20) received standard chow supplemented with 250 mg/kg body weight/d of SM. The observation period was 2 months. The ETS animals had higher values of left cardiac chamber diameters and of left ventricular mass index. SM supplementation attenuated these changes. In addition, the myocyte cross-sectional area (CSA) was lower in group C compared with the ETS groups; however, the ETS250 group had lower values of CSA compared with the ETS group. The ETS group also showed higher cardiac levels of lipid hydroperoxide (LH) compared with group C; and, groups ETS100 and ETS250 had lower concentrations of LH compared with the ETS group. Regarding energy metabolism, SM supplementation decreased glycolysis and increased the β-oxidation and the oxidative phosphorylation. There were no differences in the expression of Nrf-2, SIRT-1, NF-κB, interferon-gamma and interleukin 10. In conclusion, our results suggest that ETS induced the cardiac remodelling process. In addition, SM supplementation attenuated this process, along with oxidative stress reduction and energy metabolism modulation.Entities:
Keywords: cardiac remodelling; cigarette smoke; energy metabolism; fruit; oxidative stress
Year: 2018 PMID: 29808581 PMCID: PMC6050477 DOI: 10.1111/jcmm.13683
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.295
Morphological and functional data evaluated by echocardiography
| Variables | C group (n = 20) | ETS group (n = 20) | ETS100 group (n = 20) | ETS250 group (n = 20) |
|
|---|---|---|---|---|---|
| BW (g) | 411 (405‐423) | 369 (339‐394) | 361 (349‐391) | 366 (354‐404) | <.001 |
| HR (bpm) | 313.1 ± 54.1 | 302.1 ± 50.0 | 298.0 ± 33.7 | 302.5 ± 51.2 | .781 |
| LA area (cm2) | 22.0 ± 3.8 | 25.6 ± 5.2 | 24.1 ± 2.8 | 22.2 ± 3.5 | .017 |
| LA/BW (mm/kg) | 11.4 (11.1‐12.4) | 14.6 (13.1‐16.0) | 14.6 (13.6‐15.1) | 12.8 (12.2‐15.0) | <.001 |
| LVDD/BW (mm/kg) | 16.8 ± 1.1 | 20.3 ± 2.6 | 19.0 ± 1.5 | 18.5 ± 1.6 | <.001 |
| LVSD/BW (mm/kg) | 6.8 (6.0‐7.2) | 8.4 (7.3‐11.1) | 8.8 (7.5‐9.8) | 8.2 (7.5‐8.7) | <.001 |
| RWT | 0.47 ± 0.05 | 0.43 ± 0.07 | 0.46 ± 0.06 | 0.48 ± 0.05 | .134 |
| IMVE (g/kg) | 1.8 (1.5‐2.0) | 2.1 (1.9‐2.4) | 2.0 (1.8‐2.2) | 2.0 (1.9‐2.3) | .012 |
| EF (%) | 0.93 (0.90‐0.95) | 0.91 (0.86‐0.94) | 0.91 (0.89‐0.93) | 0.92 (0.89‐0.93) | .156 |
| FS (%) | 58.6 (54.1‐62.5) | 55.4 (48.4‐61.4) | 54.8 (52.1‐59.3) | 56.0 (52.0‐58.4) | .157 |
| IRT/RR0.5 (ms) | 0.09 ± 0.02 | 0.09 ± 0.03 | 0.08 ± 0.02 | 0.09 ± 0.02 | .563 |
| E/A | 1.6 (1.4‐1.7) | 1.7 (1.5‐2.0) | 1.8 (1.5‐2.0) | 1.7 (1.5‐1.8) | .231 |
| EDT (ms) | 49.2 ± 5.3 | 48.4 ± 8.4 | 48.7 ± 5.1 | 50.2 ± 4.5 | .790 |
BW, body weight; E/A, peak velocity of early ventricular filling/peak velocity of transmitral flow during atrial contraction; EDT, E‐wave deceleration time; EF, ejection fraction; ETS, exposed to tobacco smoke; FS, endocardial fractional shortening; HR, heart rate; IRT/RR0.5, isovolumetric relaxation time adjusted by heart rate; LA, left atrium; LVDD, LV end‐diastolic dimension; LVSD, LV end‐systolic dimension; RWT, relative wall thickness.
Data are expressed as mean ± SD or as the median (lower quartile‐upper quartile). One‐way ANOVA/Tukey.
≠ with C group.
≠ with ETS group.
Isolated heart data
| Variables | C group (n = 20) | ETS group (n = 20) | ETS100 group (n = 20) | ETS250 group (n = 20) |
|
|---|---|---|---|---|---|
| Systolic pressure (mm Hg) | 130.5 ± 12.5 | 130.6 ± 14.5 | 126.9 ± 21.5 | 133.4 ± 28.5 | .935 |
| +d | 2375 ± 378 | 2469 ± 382 | 2359 ± 599 | 2661 ± 874 | .743 |
| −d | 1797 ± 238 | 1914 ± 315 | 1734 ± 414 | 2000 ± 629 | .612 |
| DP (mm Hg) | 99.2 ± 11.5 | 104.0 ± 16.4 | 96.9 ± 20.7 | 104.4 ± 27.7 | .846 |
+dP/dt max, maximum left ventricular pressure development rate; −dP/dt max, maximum left ventricular pressure decrease rate; DP, developed pressure; ETS, exposed to tobacco smoke.
Data are expressed as mean ± SD. One‐way ANOVA/Tukey.
Morphometrical analysis
| Variables | C group (n = 20) | ETS group (n = 20) | ETS100 group (n = 20) | ETS250 group (n = 20) |
|
|---|---|---|---|---|---|
| LV (g) | 0.87 ± 0.11 | 0.90 ± 0.14 | 0.84 ± 0.09 | 0.86 ± 0.11 | .500 |
| RV (g) | 0.23 (0.20‐0.27) | 0.24 (0.19‐0.27) | 0.20 (0.19‐0.23) | 0.22 (0.19‐0.27) | .370 |
| LV/BW | 2.1 ± 0.3 | 2.5 ± 0.5 | 2.3 ± 0.2 | 2.3 ± 0.3 | .005 |
| RV/BW | 0.56 (0.49‐0.64) | 0.63 (0.52‐0.86) | 0.56 (0.52‐0.64) | 0.61 (0.53‐0.65) | .332 |
| CSA | 266.6 ± 23.2 | 347.5 ± 15.1 | 302.5 ± 5.2 | 294.7 ± 8.6 | <.001 |
BW, body weight; CSA, myocyte cross‐sectional area; ETS, exposed to tobacco smoke; LV, left ventricle; RV, right ventricle.
Data are expressed as mean ± standard deviation (SD) or as the median (lower quartile‐upper quartile). One‐way ANOVA/Tukey.
≠ with C group.
≠ with ETS group.
CSA analysis performed in 6 animals per group.
Left ventricle oxidative stress
| Variables | C group (n = 8) | ETS group (n = 8) | ETS100 group (n = 8) | ETS250 group (n = 8) |
|
|---|---|---|---|---|---|
| LH (nmol/g) | 196.4 ± 51.5 | 331.9 ± 52.9 | 207.2 ± 53.0 | 165.1 ± 40.3 | <.001 |
| CAT (μmol/g) | 75.8 ± 7.8 | 54.0 ± 7.3 | 59.6 ± 5.8 | 61.1 ± 6.5 | <.001 |
| SOD (nmol/g) | 7.9 ± 0.4 | 5.7 ± 0.4 | 7.5 ± 0.9 | 7.8 ± 0.9 | <.001 |
| GSH‐Px (nmol/g) | 39.2 ± 5.6 | 18.8 ± 3.4 | 30.0 ± 5.6 | 31.1 ± 4.3 | <.001 |
CAT, catalase; ETS, exposed to tobacco smoke; GSH‐Px, glutathione peroxidase; LH, lipid hydroperoxide; SOD, superoxide dismutase.
Data are expressed as mean ± SD. One‐way ANOVA/Tukey.
≠ with C group.
≠ with ETS group.
Energy metabolism data
| Variables | C group (n = 8) | ETS group (n = 8) | ETS100 group (n = 8) | ETS250 group (n = 8) |
|
|---|---|---|---|---|---|
| OHADH (nmol/mg) | 33.2 ± 7.8 | 20.4 ± 4.0 | 32.5 ± 7.3 | 28.3 ± 7.0 | .002 |
| PFK (nmol/g) | 135.9 ± 22.8 | 188.3 ± 22.2 | 188.3 ± 21.7 | 148.5 ± 19.0 | <.001 |
| LDH (nmol/mg) | 85.1 ± 8.8 | 140.1 ± 10.2 | 134.8 ± 12.9 | 96.8 ± 12.2 | <.001 |
| PD (nmol/g) | 211.4 ± 32.2 | 169.3 ± 23.2 | 178.2 ± 40.6 | 198.3 ± 33.9 | .067 |
| CS (nmol/mg) | 85.6 ± 8.1 | 35.7 ± 8.1 | 42.8 ± 3.4 | 52.5 ± 8.6 | <.001 |
| Complex I (nmol/mg) | 10.3 ± 1.4 | 2.8 ± 0.4 | 3.3 ± 0.4 | 8.3 ± 1.2 | <.001 |
| Complex II (nmol/mg) | 3.7 ± 0.3 | 1.9 ± 0.4 | 2.1 ± 0.4 | 3.4 ± 0.2 | <.001 |
| ATP synthase (noml/mg) | 32.3 ± 2.4 | 19.4 ± 2.5 | 19.5 ± 3.0 | 22.0 ± 3.1 | <.001 |
CS, citrate synthase; ETS, exposed to tobacco smoke; LDH, lactate dehydrogenase; OHADH, β‐hydroxyacyl coenzyme‐A dehydrogenase; PD, pyruvate dehydrogenase; PFK, phosphofructokinase.
Data are expressed as mean ± SD. One‐way ANOVA/Tukey.
≠ with C group.
≠ with ETS group.
≠ with ETS250 group.
Figure 1Western blot analysis of cardiac Nrf‐2, SIRT‐1, NF‐κB, IFN‐γ and IL‐10 among groups
Figure 2Western blot analysis of cardiac types I and III collagen among groups